Literature DB >> 20628892

Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.

Francesca Buontempo1, Tulin Ersahin, Silvia Missiroli, Serif Senturk, Daniela Etro, Mehmet Ozturk, Silvano Capitani, Rengul Cetin-Atalay, Maria Luca Neri.   

Abstract

The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is involved in cell survival and anti-apoptotic signaling. Akt has been shown to be constitutively expressed in a variety of human tumors including hepatocellular carcinoma (HCC). In this report we analyzed the status of Akt pathway in three HCC cell lines, and tested cytotoxic effects of Akt pathway inhibitors LY294002, Wortmannin and Inhibitor VIII. In Mahlavu human hepatoma cells Akt was constitutively activated, as demonstrated by its Ser473 phosphorylation, downstream hyperphosphorylation of BAD on Ser136, and by a specific cell-free kinase assay. In contrast, Huh7 and HepG2 did not show hyperactivation when tested by the same criteria. Akt enzyme hyperactivation in Mahlavu was associated with a loss of PTEN protein expression. Akt signaling was inhibited by the upstream kinase inhibitors, LY294002, Wortmannin, as well as by the specific Akt Inhibitor VIII in all three hepatoma cell lines. Cytotoxicity assays with Akt inhibitors in the same cell lines indicated that they were all sensitive, but with different IC50 values as assayed by RT-CES. We also demonstrated that the cytotoxic effect was through apoptotic cell death. Our findings provide evidence for its constitutive activation in one HCC cell line, and that HCC cell lines, independent of their Akt activation status respond to Akt inhibitors by apoptotic cell death. Thus, Akt inhibition may be considered as an attractive therapeutic intervention in liver cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20628892     DOI: 10.1007/s10637-010-9486-3

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  39 in total

1.  Live cell quality control and utility of real-time cell electronic sensing for assay development.

Authors:  Shelli L Kirstein; Josephine M Atienza; Biao Xi; Jenny Zhu; Naichen Yu; Xiaobo Wang; Xiao Xu; Yama A Abassi
Journal:  Assay Drug Dev Technol       Date:  2006-10       Impact factor: 1.738

Review 2.  mTOR, a new therapeutic target in acute myeloid leukemia.

Authors:  Christian Récher; Cédric Dos Santos; Cécile Demur; Bernard Payrastre
Journal:  Cell Cycle       Date:  2005-11-08       Impact factor: 4.534

3.  Asynchrony and commitment to die during apoptosis.

Authors:  C A Messam; R N Pittman
Journal:  Exp Cell Res       Date:  1998-02-01       Impact factor: 3.905

4.  Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma.

Authors:  Kazuaki Nakanishi; Michiie Sakamoto; Susumu Yamasaki; Satoru Todo; Setsuo Hirohashi
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

5.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

6.  Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.

Authors:  Klaus Juergen Schmitz; Jeremias Wohlschlaeger; Hauke Lang; Georgios Charalambos Sotiropoulos; Massimo Malago; Karen Steveling; Henning Reis; Vito Rosario Cicinnati; Kurt Werner Schmid; Hideo Andreas Baba
Journal:  J Hepatol       Date:  2007-10-29       Impact factor: 25.083

Review 7.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

Review 8.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

9.  Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.

Authors:  Helga B Salvesen; Ingunn Stefansson; Ellen I Kretzschmar; Paula Gruber; Nicola D MacDonald; Andy Ryan; Ian J Jacobs; Lars A Akslen; Soma Das
Journal:  Int J Oncol       Date:  2004-12       Impact factor: 5.650

10.  The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

Authors:  Alexandre Arcaro; Ana S Guerreiro
Journal:  Curr Genomics       Date:  2007-08       Impact factor: 2.236

View more
  19 in total

1.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.

Authors:  Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

2.  Co-culture of hepatoma cells with hepatocytic precursor (stem-like) cells inhibits tumor cell growth and invasion by downregulating Akt/NF-κB expression.

Authors:  Cheng-Jun Sui; Miao Xu; Wei-Qing Li; Jia-Mei Yang; Hong-Zhu Yan; Hui-Min Liu; Chun-Yan Xia; Hong-Yu Yu
Journal:  Oncol Lett       Date:  2016-09-13       Impact factor: 2.967

3.  An integrative model links multiple inputs and signaling pathways to the onset of DNA synthesis in hepatocytes.

Authors:  Jérémy Huard; Stephanie Mueller; Ernst D Gilles; Ursula Klingmüller; Steffen Klamt
Journal:  FEBS J       Date:  2012-04-10       Impact factor: 5.542

4.  Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells.

Authors:  Babu V Sajesh; Melanie Bailey; Zelda Lichtensztejn; Philip Hieter; Kirk J McManus
Journal:  Genetics       Date:  2013-09-03       Impact factor: 4.562

5.  The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.

Authors:  Carolina Simioni; Alice Cani; Alberto M Martelli; Giorgio Zauli; Ayman A M Alameen; Simona Ultimo; Giovanna Tabellini; James A McCubrey; Silvano Capitani; Luca M Neri
Journal:  Oncotarget       Date:  2015-07-10

6.  The role of PTEN - HCV core interaction in hepatitis C virus replication.

Authors:  Qi Wu; Zhubing Li; Paul Mellor; Yan Zhou; Deborah H Anderson; Qiang Liu
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

7.  Image classification of human carcinoma cells using complex wavelet-based covariance descriptors.

Authors:  Furkan Keskin; Alexander Suhre; Kivanc Kose; Tulin Ersahin; A Enis Cetin; Rengul Cetin-Atalay
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

8.  Cancer cell cytotoxicities of 1-(4-substitutedbenzoyl)-4-(4-chlorobenzhydryl)piperazine derivatives.

Authors:  Mine Yarim; Meric Koksal; Irem Durmaz; Rengul Atalay
Journal:  Int J Mol Sci       Date:  2012-06-28       Impact factor: 6.208

Review 9.  Mitochondria-Associated Endoplasmic Reticulum Membranes Microenvironment: Targeting Autophagic and Apoptotic Pathways in Cancer Therapy.

Authors:  Simone Patergnani; Sonia Missiroli; Saverio Marchi; Carlotta Giorgi
Journal:  Front Oncol       Date:  2015-07-27       Impact factor: 6.244

10.  P53 family members modulate the expression of PRODH, but not PRODH2, via intronic p53 response elements.

Authors:  Ivan Raimondi; Yari Ciribilli; Paola Monti; Alessandra Bisio; Loredano Pollegioni; Gilberto Fronza; Alberto Inga; Paola Campomenosi
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.